AI-Assisted Screening Tool Speeds Trial Eligibility Determination

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on Feb 24, 2025.

By Elana Gotkine HealthDay Reporter

MONDAY, Feb. 24, 2025 -- Compared with manual screening, an artificial intelligence (AI)-assisted patient screening tool can improve the rate of eligibility determination and enrollment for randomized clinical trials, according to a research letter published online Feb. 17 in the Journal of the American Medical Association.

Ozan Unlu, M.D., from Mass General Brigham in Somerville, Massachusetts, and colleagues developed the Retrieval Augmented Generation Enabled Clinical Trial Infrastructure for Inclusion Exclusion Review (RECTIFIER) large language model tool and tested it in a prospective, blind, randomized clinical trial within the Mass General Brigham Health System. The trial was completed within an ongoing heart failure implementation trial and included 4,476 patients who were randomly assigned. The primary outcome was time to trial eligibility determination, which was assessed using a survival analysis framework.

The researchers found that compared with patients screened manually, patients screened with the AI-assisted method achieved the primary end point of eligibility determination significantly more quickly (subdistribution hazard ratio [HR], 1.78). The eligibility rate was 20.4 and 12.7 percent for the AI-assisted screening and manual screening methods, respectively. At the end of the trial, there were 35 and 19 enrollments (1.6 and 0.9 percent, respectively) using the AI-assisted screening and manual screening methods (subdistribution HR, 1.79).

"Implementing AI-assisted screening tools like RECTIFIER enhances clinical trial efficiency and expedites the screening and recruitment process, which may lead to faster trial completion and earlier access to novel therapies for patients," the authors write.

Several authors disclosed ties to relevant organizations.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-02-25 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords